BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2476601
,
PDX1
,
G-protein-coupled receptor binding
,
Arthritis
,
Stem cell
,
Nosology
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
erlotinib
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
CYP1A1
DUSP6
LCN2
RRM2
EGR1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
FISCHER_DREAM_TARGETS
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP
DODD_NASOPHARYNGEAL_CARCINOMA_DN
KOBAYASHI_EGFR_SIGNALING_24HR_DN
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Gene expression in EGFR inhibitor resistant or sensitive pancreatic cancer
Dermal fibroblasts treated with the tyrosine kinase inhibitor erlotinib
Livers of rat exposed to variety of hepatotoxic compounds
Bronchial epithelial cells with erlotinib-induced quiescence or senescence
Lung cancer PC-9 parental cells or drug-treated and drug-tolerant persister (DTP) subpopulations
Explore Curated Studies Results
Literature
Most Relevant Literature
Erlotinib-associated interstitial pneumonitis with successful readministration.
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma…
Preparation of Erlotinib hydrochloride nanoparticles (anti-cancer drug) by RESS-C method and investi…
Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization durin…
PEGylated Erlotinib HCl Injectable Nanoformulation for Improved Bioavailability.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Erlotinib in Combination With Cetuximab
Erlotinib in Higher Risk Myelodysplastic Syndrome
Study of Ixazomib and Erlotinib in Solid Tumors
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Erlotinib and Temsirolimus for Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ